Insulin Resistance in Polycystic Ovary Syndrome Improved by Chinese Medicine Dingkun Pill (): A Randomized Controlled Clinical Trial.
10.1007/s11655-018-2947-1
- Author:
Yan DENG
1
;
Wei XUE
1
;
Yan-Fang WANG
1
;
Xiao-Hui LIU
2
;
Shi-Yang ZHU
1
;
Xiao MA
1
;
Hong-Ling ZUO
3
;
Jian-Fa JIANG
4
;
Ting-Ping ZHENG
5
;
Ai-Jun SUN
6
Author Information
1. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
2. Technology Center for Protein Sciences, School of Life Sciences, Tsinghua University, Beijing, 100084, China.
3. Department of Obstetrics and Gynecology, The Second Hospital of Hebei Medical University, Hebei, 050000, China.
4. Department of Obstetrics and Gynecology, Third Xiangya Hospital, Central South University, Changsha, 410013, China.
5. Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital Affiliated of Capital Medical University, Beijing, 100020, China.
6. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. saj_pumch@sina.com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Diane-35;
Dingkun Pill;
insulin resistance;
oral glucose tolerance tests;
polycystic ovary syndrome
- From:
Chinese journal of integrative medicine
2019;25(4):246-251
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To assess the efficacy and safety of the Chinese medicine Dingkun Pill (, DKP) on insulin resistance in women with polycystic ovary syndrome (PCOS).
METHODS:A total of 117 women with PCOS were randomly assigned to Group A (38 women), Group B (40 women), or Group C (39 women) in a randomization sequence with SAS software and a 1:1:1 allocation ratio using random block sizes of 6, and were given 7 g of oral DKP daily (Group A), 1 tablet of Diane-35 orally daily (Group B), or 7 g of oral DKP daily plus 1 tablet of Diane-35 orally daily (Group C). Patients took all drugs cyclically for 21 consecutive days, followed by 7 drug-free days. The treatment course for the 3 groups was continued for 3 consecutive months. Oral glucose tolerance tests (OGTT) were performed before treatment and again after 2 and 3 months of therapy, respectively, and homeostasis model assessment for insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) were calculated.
RESULTS:Of 117 women with PCOS, 110 completed the entire course of therapy: 35 in Group A, 36 in Group B, and 39 in Group C. After treatment, all three groups showed significant decreases in fasting glucose: at 1 h glucose decreased significantly in Group A (by 0.5 ± 1.4 mmol/L, P=0.028) and Group C (by 0.5 ± 1.2 mmol/L, P=0.045); while showing a tendency to increase in Group B (by 0.4 ± 1.9 mmol/L, P=0.238). HOMA-IR decreased significantly in Group C [by 0.5 (-2.2 to 0.5) mIU mmol/L, P=0.034]. QUICKI was significantly increased in Groups A and C (by 0.009 ± 0.02, P=0.033 and by 0.009 ± 0.027, P=0.049, respectively), while no change was observed in Group B. Repeated-measure ANOVA showed that the absolute changes in all parameters (except for glucose at 1 h), including glucose and insulin levels at all time-points during OGTT and in HbA1c, HOMA-IR, and QUICKI, were not significantly different among the 3 groups after treatment (P>0.05).
CONCLUSION:DKP or DKP combined with Diane-35 produce a slight improvement in insulin sensitivity compared with Diane-35 alone in PCOS patients (Trial Registration: ClinicalTrials.gov, NCT03264638).
